Clinical trial NCT00062283: Alanosine in Treating Patients With Cancer
Official title: A Phase II, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Intravenous SDX-102 for the Treatment of Patients With MTAP-Deficient Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Lung Cancer
Malignant Mesothelioma
Pancreatic Cancer
Sarcoma
Keywords: advanced malignant mesothelioma
recurrent malignant mesothelioma
metastatic osteosarcoma
recurrent osteosarcoma
recurrent adult soft tissue sarcoma
stage IV adult soft tissue sarcoma
chondrosarcoma
recurrent non-small cell lung cancer
stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
adenocarcinoma of the pancreas
recurrent pancreatic cancer
stage III adult soft tissue sarcoma
stage II adult soft tissue sarcoma
stage IV pancreatic cancer
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
Collaborators: name: National Cancer Institute (NCI)
First posted: 2003-06-06
Sex: ALL
Minimum age (years): 13
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: RATIONALE: Drugs used in chemotherapy such as alanosine use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well alanosine works in treating patients with soft tissue sarcoma, sarcoma of the bone, mesothelioma, non-small cell lung cancer, or pancreatic cancer.

Detailed description: OBJECTIVES:

* Determine the response rates in patients with methylthioadenosine phosphorylase (MTAP)-deficient cancer when treated with alanosine.
* Determine the time to response and duration of response in patients treated with this drug.
* Determine the progression-free survival of patients treated with this drug.
* Determine the pharmacodynamic activity of this drug in these patients, based on special imaging to measure tumor adenosine triphosphate depletion.
* Determine the pharmacokinetic activity of this drug in these patients.
* Determine the safety and tolerability of this drug in these patients.

OUTLINE: This is a nonrandomized, open-label, multicenter study.

Patients receive alanosine IV continuously on days 1-5. Treatment repeats every 21 days for up to 9 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed at 28 days.

PROJECTED ACCRUAL: A total of 50-145 patients (10-29 per tumor type) will be accrued for this study.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed malignancy of any of the following types:

  * Soft-tissue sarcoma

    * High grade
    * Chemotherapy naïve or progressive or metastatic after no more than 2 prior cytotoxic treatment regimens (not including adjuvant therapy)
  * Sarcoma of the bone (including osteosarcoma\* and chondrosarcoma)

    * High grade
    * Progressive or recurrent after no more than 2 prior cytotoxic treatment regimens
    * No newly diagnosed or chemotherapy naïve disease NOTE: \*Prior treatment with cisplatin and doxorubicin required
  * Mesothelioma

    * Unresectable
    * Chemotherapy naïve or progressive after no more than 1 prior cytotoxic chemotherapy regimen
    * Not amenable to curative treatment with surgery

      * Evidence of gross unresectability includes, but is not limited to, direct extension into the chest wall, mediastinal or hilar lymphadenopathy, pulmonary or cardiac function that is inadequate to tolerate resection, and sarcomatoid or mixed histology
  * Non-small cell lung cancer

    * Stage III with malignant pleural or pericardial effusion, stage IV, or progressive after no more than 2 prior cytotoxic chemotherapy regimens
    * No newly diagnosed or chemotherapy naïve disease
  * Pancreatic cancer

    * Stage IV adenocarcinoma after no more than 1 prior cytotoxic treatment regimen
    * No newly diagnosed or chemotherapy naïve disease
* No Ewing's sarcoma of the soft tissue or bone
* Documented absence of methylthioadenosine phosphorylase on fixed tumor specimens
* Measurable disease

  * For all tumor types, at least 1 lesion measurable by MRI or CT scan
  * Chest x-ray allowed only for clearly defined lesions surrounded by aerated lung
  * Soft tissue component of bone disease considered measurable provided it can be measured by MRI or CT scan
  * Must be outside of a previously irradiated area
* No uncontrolled CNS metastases of primary tumor under study

  * Patients with brain metastases are eligible only if the brain metastases have been treated with prior radiotherapy and/or surgery, are neurologically stable with no progressing symptoms, and are off steroids and anticonvulsants

PATIENT CHARACTERISTICS:

Age

* 18 and over (13 and over for osteosarcoma only)

Performance status

* WHO 0-2

Life expectancy

* At least 3 months

Hematopoietic

* Absolute granulocyte count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3

Hepatic

* Bilirubin no greater than 1.5 times upper limit of normal (ULN)
* Alkaline phosphatase no greater than 2.5 times ULN
* AST and ALT no greater than 2.5 times ULN (5 times ULN if liver metastases are present)

Renal

* Creatinine no greater than 1.5 times ULN

Other

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective barrier contraception during and for 4 weeks after study treatment
* No premalignant bony lesions (e.g., Paget's disease)
* No other concurrent active malignancy except completely excised nonmelanoma skin cancer or carcinoma in situ of the cervix or bladder
* No serious infection
* No medical or psychiatric condition that would preclude the achievement of the study objectives

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not specified

Chemotherapy

* See Disease Characteristics
* More than 42 days since prior nitrosoureas or mitomycin

Endocrine therapy

* See Disease Characteristics

Radiotherapy

* See Disease Characteristics
* At least 28 days since prior brain radiotherapy
* More than 28 days since prior radiotherapy to more than 50% of the bone marrow

Surgery

* See Disease Characteristics
* At least 28 days since prior thoracic or other major surgery

Other

* Recovered from prior therapy
* More than 28 days since prior cytotoxic agents
* More than 28 days since prior anticancer investigational agents
* No other concurrent anti-tumor treatment

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham Comprehensive Cancer Center
state: Alabama
city: Tucson
country: United States
facility: Arizona Cancer Center at University of Arizona Health Sciences Center
state: Arizona
city: La Verne
country: United States
facility: Wilshire Oncology Medical Group, Incorporated - La Verne
state: California
city: Los Angeles
country: United States
facility: Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center
state: California
city: Boca Raton
country: United States
facility: Lynn Regional Cancer Center West
state: Florida
city: Chicago
country: United States
facility: University of Chicago Cancer Research Center
state: Illinois
city: Skokie
country: United States
facility: Midwest Cancer Research Group, Incorporated
state: Illinois
city: New York
country: United States
facility: St. Vincent's Comprehensive Cancer Center - Manhattan
state: New York
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
city: Nashville
country: United States
facility: Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
state: Tennessee
city: Houston
country: United States
facility: MD Anderson Cancer Center at University of Texas
state: Texas
city: Houston
country: United States
facility: U.S. Oncology, Incorporated
state: Texas
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Paul A. Meyers, MD
role: STUDY_CHAIR
References: